Efficacy, innovativeness, clinical trials, endpoints, and price of drugs with FDA approval for non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Michaeli, C. T. [1 ]
Michaeli, J. C. [2 ]
Desai, A. [3 ]
Albers, S. [4 ]
Michaeli, D. T. [5 ]
机构：
[1] UMM Univ Klinikum Mannheim, Abt Personalisierte Onkol Schwerpunkt Lungenkar, Mannheim, Germany
[2] Univ Hosp Munich, Dept Gynecol & Obstet, Breast Ctr & CCC Munich, BZKF, Munich, Germany
[3] Univ Alabama Birmingham, Div Hematol & Oncol, Dept Med, Birmingham, AL USA
[4] Tech Univ Munich, Klin & Poliklinik Unfallchirurgie, Klinikum Rechts Isar, Munich, Germany
[5] Natl Ctr Tumor Dis NCT Heidelberg, Dept Med Oncol, Heidelberg, Germany
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.1386
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1331P
引用
收藏
页码：S845 / S845
页数：1
相关论文
共 50 条
  • [1] Breast cancer drugs: FDA approval, development time, efficacy, clinical benefits, innovation, trials, endpoints, quality of life, value, and price
    Michaeli, Julia Caroline
    Michaeli, Thomas
    Trapani, Dario
    Albers, Sebastian
    Dannehl, Dominik
    Wuerstlein, Rachel
    Michaeli, Daniel Tobias
    BREAST CANCER, 2024, 31 (06) : 1144 - 1155
  • [2] FDA analysis: relationship between time-to-deterioration in cough, dyspnea, and/or pain in chest to clinical endpoints in non-small cell lung cancer (NSCLC) trials
    Vallejo, Jonathon
    Fiero, Mallorie
    Zhou, Jiaxi
    Royhouse, Jessica
    Kluetz, Paul
    Sridhara, Rajeshwari
    QUALITY OF LIFE RESEARCH, 2019, 28 : S56 - S56
  • [3] Pathologic endpoints as surrogates for survival endpoints in neoadjuvant immunotherapy clinical trials for non-small cell lung cancer
    Cameron, Robert B.
    Hines, Jacobi B.
    Esposito, Alessandra
    Bestvina, Christine
    Garassino, Marina C.
    Torri, Valter
    Thawani, Rajat
    CANCER RESEARCH, 2024, 84 (06)
  • [4] Neoadjuvant therapy gains FDA approval in non-small cell lung cancer
    Leal, Ticiana A.
    Ramalingam, Suresh S.
    CELL REPORTS MEDICINE, 2022, 3 (07)
  • [5] Endpoints in Phase II Trials for Advanced Non-small Cell Lung Cancer
    Mandrekar, Sumithra J.
    Qi, Yingwei
    Hillman, Shauna L.
    Ziegler, Katie L. Allen
    Reuter, Nicholas F.
    Rowland, Kendrith M., Jr.
    Kuross, Steven A.
    Marks, Randolph S.
    Schild, Steven. E.
    Adjei, Alex A.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (01) : 3 - 9
  • [6] MOLECULAR INEQUALITY IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC) AND IMPLICATIONS FOR CLINICAL TRIALS
    Naidoo, Jarushka
    Noonan, Sinead
    Teo, Min Yuen
    Rho, Young Soo
    Clince, Janet
    Gately, Kathy
    O'Grady, Tony
    Kaye, Elaine
    Calvert, Paula
    Morris, Patrick G.
    O'Brien, Cathal
    O'Byrne, Kenneth
    Breathnach, Oscar S.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1208 - S1208
  • [7] New immunotherapeutic drugs in advanced non-small cell lung cancer (NSCLC): from preclinical to phase I clinical trials
    Rocco, Danilo
    Gregorc, Vanesa
    Della Gravara, Luigi
    Lazzari, Chiara
    Palazzolo, Giovanni
    Gridelli, Cesare
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2020, 29 (09) : 1005 - 1023
  • [8] Recent Clinical Trials in Non-Small Cell Lung Cancer
    Ramalingam, Suresh
    Belani, Chandra P.
    CURRENT CANCER THERAPY REVIEWS, 2006, 2 (01) : 81 - 99
  • [9] Gender, age, and ethnic representation in non-small cell lung cancer (NSCLC) US registration trials: FDA review
    Malik, S. M.
    Farrell, A. T.
    Xu, Q.
    Sridhara, R.
    Pazdur, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [10] Pharmacogenomic applications in the management of Non-Small Cell Lung Cancer (NSCLC): from clinical trials to clinical practice
    Simon, George
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S302 - S304
12345